OA01.05 Three-year Outcomes per PD-L1 Status and Continued Cemiplimab Beyond Progression + Chemotherapy: EMPOWER-Lung 1 von Garassino, M.C., Kilickap, S., Özgüroğlu, M., Sezer, A., Gumus, M., Bondarenko, I., Gogishvili, M., Nechaeva, M., Schenker, M., Cicin, I., Fuang, H.G., Kulyaba, Y., Dvorkin, M., Zyuhal, K., Scheusan, R.-I., He, X., Kaul, M., Okoye, E., Li, Y., Li, S., Pouliot, J.-F., Seebach, F., Lowy, I., Gullo, G., Rietschel, P.

Volltext

163P Health-related quality of life (HRQoL) with pembrolizumab (pembro) vs chemotherapy (chemo) in platinum-pretreated recurrent or metastatic (R/M) nasopharyngeal cancer (NPC): Ph... von Chan, A.T.C., Lee, H.F.V., Hong, R-L., Ahn, M-J., Chong, W.Q., Kim, S-B., Fuang, H.G., Caguioa, P.B., Ngamphaiboon, N., Ho, C., Abdul Aziz, M.A.S., Ng, Q.S., Yen, C.J., Soparattanapaisarn, N., Ngan, R., Kho, S.K., Wang, L., Swaby, R., Saraf, S., Siu, L.L.

Volltext